Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:BIIB News 30 October 2025 - 22 December 2025

Biogen (BIIB) Stock News Today (Dec. 22, 2025): QALSODY Data, Nasdaq-100 Exit, and Analyst Forecasts

Biogen (BIIB) Stock News Today (Dec. 22, 2025): QALSODY Data, Nasdaq-100 Exit, and Analyst Forecasts

Biogen Inc. (NASDAQ: BIIB) is in focus on Monday, December 22, 2025—a day that combines company-specific clinical headlines with a major index event for the stock. Investors are weighing fresh long‑term data for QALSODY (tofersen) in a rare genetic form of ALS, Biogen’s public statement honoring co‑founder Charles Weissmann, and the market mechanics of Biogen’s removal from the Nasdaq‑100, which becomes effective today. At the same time, Wall Street’s outlook remains mixed but active: recent analyst notes span “Reduce/Hold” to “Outperform” with price targets stretching from the low‑$140s to above $200, reflecting a debate over how quickly newer products—especially Leqembi
22 December 2025
·
Biogen Stock Forecast for the Week Ahead (Dec. 22–26, 2025): BIIB Near 52-Week High as Leqembi Momentum Meets an Analyst Split

Biogen Stock Forecast for the Week Ahead (Dec. 22–26, 2025): BIIB Near 52-Week High as Leqembi Momentum Meets an Analyst Split

Biogen Inc. (NASDAQ: BIIB) heads into the Christmas week with its stock hovering just below a recent high, a fresh spike in trading volume, and a narrative that’s increasingly dominated by one question: can the company turn Leqembi’s momentum into a durable growth engine while legacy revenue lines mature and competition intensifies? As of Sunday, December 21, 2025, BIIB is coming off a strong finish to last week—closing Friday, Dec. 19 at $174.80, up 2.88% on the session, with unusually heavy volume for the name. MarketWatch That closing level still sits below the 52-week high of $185.17 (set Nov. 24),
21 December 2025
··
Biogen Stock (NASDAQ: BIIB) News and Forecasts for Dec. 20, 2025: RBC’s $210 Target, Leqembi Catalysts, and What Investors Are Watching

Biogen Stock (NASDAQ: BIIB) News and Forecasts for Dec. 20, 2025: RBC’s $210 Target, Leqembi Catalysts, and What Investors Are Watching

Biogen Inc. stock (NASDAQ: BIIB) is ending the week on a stronger note after a sharp, high-volume move on Friday’s session—an attention-grabbing setup heading into late December when liquidity often thins and headlines can move shares quickly. As of Saturday, December 20, 2025 (with U.S. markets closed), BIIB is effectively reflecting Friday, Dec. 19’s close of $174.80, up 2.88% on the day. Trading activity stood out: volume hit roughly 15.0 million shares, far above the recent ~1.9 million 50-day average—an unusual spike that often signals institutional participation rather than routine retail churn. MarketWatch+1 Below is a complete, publication-ready breakdown of
20 December 2025
··
Biogen Stock (BIIB) After-Hours on Dec. 19, 2025: Why Shares Jumped, Where They Closed After the Bell, and What to Watch Before the Next Market Open

Biogen Stock (BIIB) After-Hours on Dec. 19, 2025: Why Shares Jumped, Where They Closed After the Bell, and What to Watch Before the Next Market Open

Biogen Inc. (NASDAQ: BIIB) finished Friday, December 19, 2025 with a strong gain and unusually heavy trading volume, then edged higher in extended trading—capping a session dominated by fresh analyst commentary and renewed attention on the company’s Alzheimer’s and pipeline narrative. BIIB shares rose 2.88% to close at $174.80 in regular trading, with volume jumping to roughly 15 million shares, far above typical recent levels—an important signal that the day’s move wasn’t just a low-liquidity drift. MarketWatch Biogen stock price today: BIIB closes at $174.80 on heavy volume Friday’s move stood out for two reasons: From a trading-range standpoint, the
20 December 2025
·
BIIB Stock Today: Biogen Hits New 52‑Week High After Novo Nordisk Alzheimer’s Trial Failure (Nov. 24, 2025)

BIIB Stock Today: Biogen Hits New 52‑Week High After Novo Nordisk Alzheimer’s Trial Failure (Nov. 24, 2025)

Biogen Inc. (NASDAQ: BIIB) shares surged to fresh 52‑week highs on Monday, November 24, 2025, as investors reacted to a high‑profile Alzheimer’s drug failure at Novo Nordisk and a new immunology partnership with Dayra Therapeutics. By the closing bell, BIIB stock finished at $177.42, up about 1.2% from Friday’s close of $175.30. The stock traded as high as $185.17 intraday, with volume just over 2.0 million shares, roughly in line with its recent average. StockAnalysis Over the last six months, Biogen has climbed roughly 40%, and about 11% over the past year, reflecting renewed confidence in its Alzheimer’s and neurology
24 November 2025
··
Biogen Stock Slides on Q3 Beat as Guidance Cut Shocks Investors

Biogen Stock Slides on Q3 Beat as Guidance Cut Shocks Investors

Biogen Inc. (Nasdaq: BIIB) is a leading neuroscience biotech known for multiple sclerosis and rare-disease therapiests2.tech. On Oct. 30, 2025 the stock dipped after a mixed earnings release. The company beat Q3 expectations – adjusted EPS $4.81 vs. $3.88 est and $2.53 B revenue vs. $2.34 B estng.investing.com – but lowered its full-year outlook. Biogen now expects 2025 non-GAAP EPS of $14.50–$15.00 (previously $15.50–16.00), citing an anticipated ~$1.25 per-share charge in Q4 for recent R&D dealsreuters.comreuters.com. CEO Chris Viehbacher spun the quarter positively, noting “we delivered another quarter of strong financial performance driven by … momentum in our launch products [and] resilience
30 October 2025
··

Stock Market Today

Intel stock jumps on China server CPU delays as traders map the week ahead

Intel stock jumps on China server CPU delays as traders map the week ahead

7 February 2026
Intel shares rose 4.87% to $50.59 Friday, trailing gains by Nvidia and Broadcom as chip stocks rallied. Sources said Intel and AMD warned Chinese customers of longer waits and higher prices for some server CPUs, with Intel lead times reaching six months. Intel said China accounts for over 20% of its revenue. Investors await key U.S. jobs and inflation data next week.
IRS tax refund delays? Watchdog flags staffing crunch as 2026 filing season ramps up

IRS tax refund delays? Watchdog flags staffing crunch as 2026 filing season ramps up

7 February 2026
IRS staffing has dropped to 2021 levels as the 2026 tax filing season begins, according to a Treasury watchdog. The agency faces a backlog of about 2 million returns, 129% above pre-pandemic levels. Most e-filers using direct deposit still get refunds within 21 days, but paper filings and amended returns could see delays. The IRS lowered its call-answer target to 70% for this season.
Plug Power stock jumps 12% after vote setback, with Feb 17 share decision in focus

Plug Power stock jumps 12% after vote setback, with Feb 17 share decision in focus

7 February 2026
Plug Power shares rose 11.6% Friday to $2.08 after a sharp drop the previous day, as attention shifted to a Feb. 17 shareholder vote on expanding authorized shares. The company failed to secure enough votes earlier this week and is urging overseas holders to participate. CEO Andy Marsh cited difficulties for European investors in casting ballots. A reverse stock split remains possible if the proposal fails.
Go toTop